LY3321367 (Eli Lilly), an anti-TIM-3 fully human IgG1 monoclonal ab known to block Gal-9:TIM-3 binding [240], was well-tolerated and had moderate anti-tumor activity as a monotherapy or when administered in combination with LY3300054 (Eli Lilly), an anti-PD-L1 ab in patients with advanced relapsed solid tumors [241]. This evidence concerns the gene LGALS9 and neoplasm.